Severe Relapse of Vaccine-Induced Guillain–Barré Syndrome After Treatment With Nivolumab

We present a patient who developed a severe and fatal relapse of postvaccination GBS after he was treated with nivolumab, a monoclonal antibody directed to programmed death–1 (PD-1), during a GBS treatment-related fluctuation. We recommend that caution be exercised in starting treatment with PD-1 inhibitors in the acute stage or early in the recovery period of GBS.
Source: Journal of Clinical Neuromuscular Disease - Category: Neurology Tags: Case Review Source Type: research